NeuroAid Therapy Shows Positive Results in Alzheimer's Disease

Alzheimer's is a progressive brain disorder affecting memory, thinking, and behavior. It's a common form of dementia, affecting millions worldwide. There is currently no cure for Alzheimer's, but there are medications that can help manage its symptoms. MLC601 and MLC901 (NeuroAid) are medications that have shown neuroprotective and neuroregenerative properties.

Clinical Trial

Researchers investigated the long-term benefits of NeuroAid in patients with Alzheimer's disease. The study included patients diagnosed with Alzheimer's disease based on DSM-IV criteria. The patients were given MLC601 for four years and then switched to MLC901 for another four years.

The researchers used Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) to assess the patient's cognitive function. They also monitored adverse events (AEs) and abnormal findings in physical examinations or lab tests to evaluate safety.

Results

The researchers found significant changes in the mean MMSE and ADAS-cog scores. These results suggest that MLC601 and MLC901 may effectively manage cognitive symptoms in patients with Alzheimer's disease. The study also showed that MLC601 and MLC901 are safe for long-term use in Alzheimer's patients, with no significant adverse events reported during the eight-year treatment period.

Conclusion

This study provides essential information on the long-term benefits and safety of MLC601 and MLC901 in Alzheimer's patients. While further research is needed, these medications show promise in managing the cognitive symptoms of Alzheimer's disease and improving the quality of life for affected individuals.
__________

Share this article with a friend: